Pharma Surge
Pharma Surge
Intelligence Layer
🇺🇸·Apr 7Research

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology PipelineTubuli

Publisher

F
Frazier Life Sciences

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Frazier Life Sciences
Region
USA
Scope
Research
Published
April 7, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on frazierls.com

Leave the platform to read the original full article on the publisher site.

Source: Frazier Life Sciences

Scope: Research

Open original article
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology PipelineTubuli | Pharma Surge